Figure 2

MTT assay of sensitive and resistant breast cancer cells treated with various treatment strategies. (A) Sensitive MDA-MB-231 and MDA-MB-468 cells were treated with various doses of docetaxel for 48 h and MTT assay was performed. (B) MTT assay was performed to determine the IC50 values of docetaxel in resistant MDA-MB-231R and MDA-MB-468R cells. (C) MDA-MB-231R cells were treated with Iturin A or combination of Iturin A along with 50 nM docetaxel for 48 h. The IC50 values Iturin A were determined. (D) MDA-MB-231R cells were treated with Iturin A or combination of Iturin A along with 50 nM docetaxel. The IC50 values Iturin A were determined. (E) MTT assay to determine IC50 of Docetaxel in presence of Iturin A (1/4th IC50 dose of Iturin A) in resistant cells. (F) IC50 values of Docetaxel and Iturin A were shown in various treatment strategies.